HEALTHY ENVIRONMENTS a Compilation of Substances Linked to Asthma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Molecular Cloning of an O-Methyltransferase from Adventitious Roots of Carapichea Ipecacuanha
100605 (016) Biosci. Biotechnol. Biochem., 75 (1), 100605-1–7, 2011 Molecular Cloning of an O-Methyltransferase from Adventitious Roots of Carapichea ipecacuanha y Bo Eng CHEONG,1 Tomoya TAKEMURA,1 Kayo YOSHIMATSU,2 and Fumihiko SATO1; 1Division of Integrated Life Science, Graduate School of Biostudies, Kyoto University, Oiwake-cho, Kitashirakawa, Sakyo-ku, Kyoto 606-8502, Japan 2Research Center for Medicinal Plant Resources, National Institute of Biomedical Innovation, 1-2 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan Received August 20, 2010; Accepted October 5, 2010; Online Publication, January 7, 2011 [doi:10.1271/bbb.100605] Carapichea ipecacuanha produces various emetine- industrial production.2) Whereas metabolic engineering type alkaloids, known as ipecac alkaloids, which have in alkaloid biosynthesis has also been explored to long been used as expectorants, emetics, and amebicides. improve both the quantity and the quality of several In this study, we isolated an O-methyltransferase cDNA alkaloids,3) biosynthetic enzymes and their genes in from this medicinal plant. The encoded protein ipecac alkaloids are still limited, except for the recent (CiOMT1) showed 98% sequence identity to IpeOMT2, isolation of glycosidases and O-methyltransferases.4,5) which catalyzes the 70-O-methylation of 70-O-demethyl- Ipecac alkaloids are synthesized from the condensa- cephaeline to form cephaeline at the penultimate step tion of dopamine derived from tyrosine, for isoquinoline ofAdvance emetine biosynthesis (Nomura and Kutchan, ViewJ. Biol. moieties, and from secologanin, as a monoterpenoid Chem., 285, 7722–7738 (2010)). Recombinant CiOMT1 molecule (Fig. 1). This Pictet-Spengler-type condensa- showed both 70-O-methylation and 60-O-methylation tion yields two epimers, (R)-N-deacetylipecoside and activities at the last two steps of emetine biosynthesis. -
A Rapid and Robust Method for Determination of 35 Phthalates in Influent, Effluent and Biosolids from Wastewater Treatment Plants
37th International Symposium on Halogenated Persistent Organic Pollutants Vancouver, Canada August 20-25, 2017 Page 1 – June-14-17 Page 2 – June-14-17 Page 3 – June-14-17 A Rapid and Robust Method for Determination of 35 Phthalates in Influent, Effluent and Biosolids from Wastewater Treatment Plants Tommy BISBICOS, Grazina PACEPAVICIUS and Mehran ALAEE Science and Technology Branch, Environment and Climate Change Canada Burlington, Ontario Canada L7S 1A1 Polyvinyl Chloride (PVC) • PVC was accidentally synthesized in 1835 by French chemist Henri Victor Regnault • Ivan Ostromislensky and Fritz Klatte both attempted to use PVC in commercial products, • But difficulties in processing the rigid, sometimes brittle polymer blocked their efforts. • Waldo Semon and the B.F. Goodrich Company developed a method in 1926 to plasticize PVC by blending it with various additives. • The result was a more flexible and more easily processed material that soon achieved widespread commercial use. From Wikipedia; accessed Oct, 2014 Plasticizers • Most vinyl products contain plasticizers which dramatically improve their performance characteristic. The most common plasticizers are derivatives of phthalic acid. • The materials are selected on their compatibility with the polymer, low volatility levels, and cost. • These materials are usually oily colorless substances that mix well with the PVC particles. • 90% of the plasticizer market is dedicated to PVC • worldwide annual production of phthalates in 2010 was estimated at 4.9 million tones* From Wikipedia; accessed Oct, 2014; and Emanuel C (2011) Plasticizer market update. http://www.cpsc.gov/about/cpsia/chap/spi.pdf (accessed March, 2014). Phthalate Uses • Plasticizers: – Wire and cable, building and construction, flooring, medical, automotive, household etc., • Solvents: – Cosmetics, creams, fragrances, candles, shampoos etc. -
Consumer Safety Compliance Standards for Use with These New Testing Regulations
Your Science Is Our Passion® Consumer Safety Analytical Standards for Consumer Safety Compliance New regulations are constantly being enacted to protect consumers from a variety of potentially dangerous compounds and elements. Recent global regulations have restricted levels of heavy metals in consumer products and waste electronics. Regulations have also been enacted to control a variety of phthalates in children’s products. SPEX CertiPrep has continued to lead the Certified Reference Materials field by creating a line of Consumer Safety Compliance Standards for use with these new testing regulations. For additional product information, please visit www.spexcertiprep.com/inorganic-standards/consumer-safety-standards-inorganic for Inorganic products and www.spexcertiprep.com/organic-standards/consumer-safety-standards-organic for Organic products. Phthalates in Polyvinyl Chloride (PVC) Polyvinyl chloride, or PVC, is a very common plastic used in a wide range of common consumer products, from children’s toys and care items to building and construction materials. In the US, ASTM and the CPSC have designated methods for testing children’s toys and childcare articles for compliance with the restricted use of six designated phthalates: DBP, BBP, DEHP, DNOP, DIDP, and DINP. SPEX CertiPrep is proud to offer the first Certified Reference Materials for phthalates in polyvinyl chloride produced under the guidelines of ISO 9001:2015, ISO/IEC 17025:2017 and ISO 17034:2016. Designed for Methods: • US Methods CPSC-CH-C1001-09.3 • ASTM D7823-13 • EU -
Postprint: International Journal of Food Science and Technology 2019, 54
1 Postprint: International Journal of Food Science and Technology 2019, 54, 2 1566–1575 3 Polyphenols bioaccessibility and bioavailability assessment in ipecac infusion using a 4 combined assay of simulated in vitro digestion and Caco-2 cell model. 5 6 Takoua Ben Hlel a,b,*, Thays Borges c, Ascensión Rueda d, Issam Smaali a, M. Nejib Marzouki 7 a and Isabel Seiquer c 8 aLIP-MB laboratory (LR11ES24), National Institute of Applied Sciences and Technology, 9 Centre urbain nord de Tunis, B.P. 676 Cedex Tunis – 1080, University of Carthage, Tunisia. 10 bDepartment of Biology, Faculty of Tunis, University of Tunis El Manar, 11 Tunis, Tunisia 12 cDepartment of Physiology and Biochemistry of Animal Nutrition, Estación Experimental del 13 Zaidín (CSIC), Camino del Jueves s/n, 18100 Armilla, Granada, Spain. 14 dInstitute of Nutrition and Food Technology José Mataix Verdú, Avenida del Conocimiento 15 s/n. Parque Tecnológico de la Salud, 18071 Armilla., Granada, Spain. 16 17 * Corresponding author: Takoua Ben Hlel. E-mail: [email protected]. Tel.: +216 18 53 831 961 19 Running title : Antioxidant potential of Ipecac infusion 20 1 21 Abstract: 22 In this report, we investigated for the first time the total polyphenols content (TPC) and 23 antioxidant activity before and after digestion of Carapichea ipecacuanha root infusion, 24 better known as ipecac, prepared at different concentrations. An in vitro digestion system 25 coupled to a Caco-2 cell model was applied to study the bioavailability of antioxidant 26 compounds. The ability of ipecac bioaccessible fractions to inhibit reactive oxygen species 27 (ROS) generation at cellular level was also evaluated. -
WO 2017/004282 Al 5 January 2017 (05.01.2017) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/004282 Al 5 January 2017 (05.01.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/35 (2006.01) A61K 8/37 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 16/040224 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 29 June 2016 (29.06.2016) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/186,240 29 June 2015 (29.06.2015) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: TAKASAGO INTERNATION CORPORA¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TION (USA) [US/US]; 4 Volvo Drive, Rockleigh, NJ TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 07647 (US). -
The Breath of Life: Respiratory Function and Botanical Medicine
Applied Phytotherapeutics The Breath of Life: Respiration By Terry Willard ClH, PhD, Todd Caldecott ClH Session 3 The Breath of Life: Respiratory Function and Botanical Medicine Introduction We usually take one of the most fundamental and transformative elements of life for granted: breathing. Through the breath, we share air with all other humans and many forms of life on the planet; we form a oneness with the trees and other plant life through our symbiotic exchange of oxygen and carbon dioxide exchange relationship with them through the oxygen and carbon dioxide exchange. We breathe each other in! ©2019 Wild Rose College of Natural Healing All Rights Reserved. 1 Applied Phytotherapeutics The Breath of Life: Respiration By Terry Willard ClH, PhD, Todd Caldecott ClH Session 3 This connects us deeply with the ecology of the planet, as well as states of Being. Remember, the origin of the word “inspiration” comes from the concept of bringing the breath of spirit into you. Every time we breathe in, we not only bring air into our lungs but Prana as well. The two Lungs Hug our Heart with each Breath. Hugged by Prana. Breathing is primarily an autonomic process that most of us are unaware of until some stressor—be it strenuous exercise or the induction of fight or flight mechanisms—calls our attention to it. We especially become conscious of the act of breathing when we cannot breathe, for example when swimming or trapped underwater, or because of a disease such as asthma or anaphylaxis. Breath is our most immediate and vital form of nourishment, and from an Ayruvedic perspective, is synonymous with the flow of consciousness, and all activities of the body. -
CAS 84-69-5 Diisobutyl Phthalate (DIBP)
CAS 84-69-5 Diisobutyl phthalate (DIBP) Toxicity The European Union classified DIBP as a reproductive Substance of Very High Concern (SVHC).1 A 2011 study observed decreased testicular testosterone in male rats fed DIBP for 4 days.2 Borch et al. 2006 found male offspring of female rats exposed to DIBP from gestation day 7 to gestation day 20 or 21 had significantly reduced anogenital distance.3 The Chronic Hazard Advisory Panel (CHAP) determined, due to toxicological profile similarities to Dibutyl phthalate (DBP), exposure to DIBP contributes to a cumulative antiandrogenic effect with other phthalates and should be permanently banned in children’s toys and child care articles at levels greater than 0.1 percent.4 In 2017 the CPSC permanently banned DIBP in children’s toys and childcare articles at levels greater than 0.1 percent.5 Exposure The 2015 National Health and Nutrition Examination Survey (NHANES) monitored a metabolite of DIBP in human urine, and the levels appear to be increasing.6 Metabolites of DIBP were detected in the urine of pregnant Danish women in a 2010-2012 study.7 A significant correlation was found between DIBP metabolite concentrations in the urine of Danish children and increased levels of DIBP in bedroom dust and day care centers.8 Other DIBP is used as a substitute ingredient to di-n-butyl phthalate (DBP) due to structural similarities, therefore, its’ presence in products may increase.3 References 1. European Commission, Endocrine disruptor priority list. Retrieved from: http://ec.europa.eu/environment/chemicals/endocrine/strategy/substances_en.htm 2. Hannas, B.R., Lambright, C.S., Furr, J., Howdeshell, K.L., Wilson, V.S., Gray, L.E., Jr. -
Chemical Resistance of Plastics
(c) Bürkle GmbH 2010 Important Important information The tables “Chemical resistance of plastics”, “Plastics and their properties” and “Viscosity of liquids" as well as the information about chemical resistance given in the particular product descriptions have been drawn up based on information provided by various raw material manufacturers. These values are based solely on laboratory tests with raw materials. Plastic components produced from these raw materials are frequently subject to influences that cannot be recognized in laboratory tests (temperature, pressure, material stress, effects of chemicals, construction features, etc.). For this reason the values given are only to be regarded as being guidelines. In critical cases it is essential that a test is carried out first. No legal claims can be derived from this information; nor do we accept any liability for it. A knowledge of the chemical and mechanical Copyright This table has been published and updated by Bürkle GmbH, D-79415 Bad Bellingen as a work of reference. This Copyright clause must not be removed. The table may be freely passed on and copied, provided that Extensions, additions and translations If your own experiences with materials and media could be used to extend this table then we would be pleased to receive any additional information. Please send an E-Mail to [email protected]. We would also like to receive translations into other languages. Please visit our website at http://www.buerkle.de from time to Thanks Our special thanks to Franz Kass ([email protected]), who has completed and extended these lists with great enthusiasm and his excellent specialist knowledge. -
Appendix B Reproductive and Other Toxicology
Report to the U.S. Consumer Product Safety Commission by the CHRONIC HAZARD ADVISORY PANEL ON PHTHALATES AND PHTHALATE ALTERNATIVES July 2014 APPENDIX B REPRODUCTIVE AND OTHER TOXICOLOGY TABLE OF CONTENTS 1 Introduction ............................................................................................................................. 1 1.1 Nonreproductive Toxicity ................................................................................................ 2 2 Permanently Banned Phthalates .............................................................................................. 3 2.1 Di-n-Butyl Phthalate (DBP) ............................................................................................. 3 2.1.1 Human Data .............................................................................................................. 3 2.1.2 Animal Data .............................................................................................................. 4 2.1.3 Studies Reported Since the NTP-CERHR Report in 2000 ....................................... 4 2.2 Butylbenzyl Phthalate (BBP) ........................................................................................... 6 2.2.1 Human Data .............................................................................................................. 6 2.2.2 Animal Data .............................................................................................................. 6 2.2.3 Studies Reported Since the NTP-CERHR Report in 2003 ...................................... -
Chronic Hazard Advisory Panel on Phthalates and Phthalate Alternatives
Report to the U.S. Consumer Product Safety Commission by the CHRONIC HAZARD ADVISORY PANEL ON PHTHALATES AND PHTHALATE ALTERNATIVES July 2014 U.S. Consumer Product Safety Commission Directorate for Health Sciences Bethesda, MD 20814 Chronic Hazard Advisory Panel on Phthalates and Phthalate Alternatives Chris Gennings, Ph.D. Virginia Commonwealth University Richmond, VA Russ Hauser, M.D., Sc.D., M.P.H. Harvard School of Public Health Boston, MA Holger M. Koch, Ph.D. Ruhr University Bochum, Germany Andreas Kortenkamp, Ph.D. Brunel University London, United Kingdom Paul J. Lioy, Ph.D. Robert Wood Johnson Medical School Piscataway, NJ Philip E. Mirkes, Ph.D. University of Washington (retired) Seattle, WA Bernard A. Schwetz, D.V.M., Ph.D. Department of Health and Human Services (retired) Washington, DC TABLE OF CONTENTS LIST OF TABLES ....................................................................................................................... iv LIST OF FIGURES ..................................................................................................................... vi ABBREVIATIONS ..................................................................................................................... vii 1 Executive Summary .............................................................................................................. 1 2 Background and Strategy................................................................................................... 11 2.1 Introduction and Strategy Definition ........................................................................... -
Therapy for Alcohol Use Disorder: an Fmri Study
ORIGINAL RESEARCH published: 28 September 2017 doi: 10.3389/fnbeh.2017.00182 The Neurobiological Mechanism of Chemical Aversion (Emetic) Therapy for Alcohol Use Disorder: An fMRI Study Ralph L. Elkins 1, Todd L. Richards 2, Robert Nielsen 1, Richard Repass 1, Henriettae Stahlbrandt 2 and Hunter G. Hoffman 2, 3* 1 Department of Medical Research, Schick Shadel Hospital, Seattle, WA, United States, 2 Department of Radiology, Integrated Brain Imaging Center, University of Washington, Seattle, WA, United States, 3 Human Photonics Lab, Mechanical Engineering, University of Washington, Seattle, WA, United States A recent NIH epidemiology study found the lifetime prevalence of alcohol use disorder in the United States to be 29%. Alcohol drinking behavior is strongly “learned” via pleasure center activation/reinforcement. Alcohol craving is a powerful desire to drink alcoholic beverages. Craving was added as one of the defining criteria for alcohol use disorder in DSM5, and craving reduction is becoming an increasingly important treatment goal. In the current study, patients with alcohol use disorder received 10 days of inpatient multi-modal treatments at Schick Shadel Hospital (SSH) of Seattle. Edited by: The treatments included five chemical aversion conditioning sessions that associated Antonella Gasbarri, alcohol cues (and alcohol) with nausea and emesis. All patients met DSM4 criteria for University of L’Aquila, Italy alcohol use disorder, were heavy drinkers, and reported craving alcohol pre-treatment. Reviewed by: Eun Lee, Craving reduction was one of the primary treatment goals. This is the first fMRI study to Yonsei University, South Korea measure the effects of chemical aversion therapy on alcohol craving-related brain activity. -
Requirement for High Codeine Lines.Docx
Biosynthetic regulation of the major opiates in Papaver somniferum Fergus Meade Doctor of Philosophy University of York Biology September 2015 Abstract Opium poppy, Papaver somniferum, is the sole source of the analgesic alkaloids morphine and codeine as well as thebaine, a precursor for semi-synthetic opiates. T6ODM (thebaine 6- O-demethylase) and CODM (codeine O-demethylase) are dioxygenases involved in morphine biosynthesis and represent promising targets for metabolic engineering of the morphinan alkaloid pathway through reverse genetic screening. An EMS (ethyl methanesulfonate)- mutagenised population of a morphine accumulating cultivar (>4000 plants) was screened for mutations in CODM and T6ODM. Although nonsense mutations were found in both, complete metabolic blocks and codeine and thebaine were not observed owing to the presence of multiple copies of these genes in the genome. Crosses and further mutagenesis were attempted to produce new cultivars of opium poppy with increased yields of codeine and thebaine. 2 Table of Contents ABSTRACT .............................................................................................................................................. 2 TABLE OF CONTENTS ......................................................................................................................... 3 LIST OF FIGURES ............................................................................................................................... 11 LIST OF TABLES ...............................................................................................................................